CDK4 and triple-negative breast carcinoma: In 2022, Xiaoxing Wu et al. identified a series of SHP2 and CDK4 dual inhibitors, including Compound 48 (Figure 9) with notable SHP2 (IC50 = 4.3 nM) and CDK4 (IC50 = 18.2 nM) inhibitory activity, for triple-negative breast cancer (TNBC) treatment [62].